

8. Bibliography

1. David S, Hamilton JP. Drug-induced liver injury. *US Gastroenterol Hepatol Rev.* 2010; 6:73–80.
2. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology.* 2013;144(7):1419–25. doi: 10.1053/j.gastro.2013.02.006
3. Chalasani N, Bonkovsky HL, Fontana RJ, Lee WM, Stolz A, Talal AH, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. *Gastroenterology.* 2015;148(7):1340–52. e7. doi: 10.1053/j.gastro.2015.03.006.
4. Bjornsson ES. Drug-induced liver injury due to antibiotics. *Scand J Gastroenterol.* 2017;52(6–7):617–23. doi:10.1080/00365521.2017.1291719.
5. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. Role of chloramphenicol in bloodstream infections due to vancomycin-resistant *Enterococcus*. *Clin Infect Dis.* 1998;27(5):1259–65.
6. Li CH, Cheng YW, Liao PL, Yang YT, Kang JJ. Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. *Toxicol Sci.* 2010;116(1):140–50. doi:10.1093/toxsci/kfq085.
7. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. *Toxicol Sci.* 2007;97(2):539–47. doi:10. /toxsci/kfm052.
8. National Toxicology Program. RoC Profile: Chloramphenicol. 15th Rep Carcinog. 2021. Available from: <https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/content/profiles/chloramphenicol.pdf>

9. Suárez-Rivero JM, Villanueva-Paz M, de Dios R, González-Gallego J, Cayuela ML. Mitochondria and antibiotics: for good or for evil? *Biomolecules*. 2021;11(7):1050. doi:10.3390/biom11071050.
10. Wu L, Mo W, Feng J, Li J, Yu Q, Li S, et al. Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1 α pathway. *Br J Pharmacol*. 2020;177(16):3760–77. doi:10.1111/bph.15099.
11. Yamashita E. Let astaxanthin be thy medicine. *Pharma Nutr*. 2015;3(4):115–22. doi:10.1016/j.phanu.2015.09.001.
12. Li J, Guo C, Wu J. Astaxanthin in liver health and disease: a potential therapeutic agent. *Drug Des Devel Ther*. 2020; 14:2275–85. doi:10.2147/DDDT.S230749.
13. Zhao X, Wang J, Deng Y, Yang Q, Liu Z, et al. Quercetin as a protective agent for liver diseases: a comprehensive review. *Phytother Res*. 2021;35(9):4727–47. doi:10.1002/ptr.7104.
14. Liu X, Zhang Y, Liu L, et al. Protective and therapeutic effects of nanoliposomal quercetin on acute liver injury in rats. *BMC Pharmacol Toxicol*. 2020; 21:11. doi:10.1186/s40360-020-0388-5.
15. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. *Drug Discov Today*. 2021;26(1):141–54. doi:10.1016/j.drudis.2020.10.013.
16. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL. Linezolid-induced inhibition of mitochondrial protein synthesis. *Clin Infect Dis*. 2006;42(8):1111–7. doi:10.1086/501357.
17. Li C, Zhou HM. The role of manganese superoxide dismutase in inflammation defense. *Enzyme Res*. 2011; 2011:387176. doi:10.4061/2011/387176.
18. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures,

- evolution, and expression. *Free Radic Biol Med.* 2002;33(3):337–349. doi:10.1016/S0891-5849(02)00905-X.
19. Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. *J Cell Biochem.* 2006;97(4):673–683. doi:10.1002/jcb.20720.
20. Wu Z, Puigserver P, Andersson U, Zhang C, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell.* 1999;98(1):115–124. doi:10.1016/S0092-8674(00)80611-X.
21. Tiranti V, Galimberti C, Nijtmans L, et al. Characterization of SURF-1 expression and Surf-1P function in Leigh syndrome patients. *Hum Mol Genet.* 1999;8(13):2533–2540. doi:10.1093/hmg/8.13.2533.
22. Zhu Z, Yao J, Johns T, et al. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. *Nat Genet.* 1998;20(4):337–343. doi:10.1038/3837.
23. Ekstrand MI, Falkenberg M, Rantanen A, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. *Hum Mol Genet.* 2004;13(9):935–944. doi:10.1093/hmg/ddh109.
24. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. *Physiol Rev.* 2008;88(2):611–638. doi:10.1152/physrev.00025.2007.
25. Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. *Nature.* 2002;415(6867):96–99. doi:10.1038/415096a.
26. Krauss S, Zhang CY, Lowell BB. The mitochondrial uncoupling-protein homologues. *Nat Rev Mol Cell Biol.* 2005;6(3):248–261. doi:10.1038/nrm1592.
27. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. *Arch Toxicol.* 2015;89(3):327–334. doi:10.1007/s00204-015-1456-2.
28. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. *Am J Gastroenterol.* 2014;109(7):950–966. doi:10.1038/ajg.2014.131.

29. Suk KT, Kim DJ. Drug-induced liver injury: present and future. *Clin Mol Hepatol*. 2012;18(3):249–257. doi:10.3350/cmh.2012.18.3.249.
30. Larson AM. Acetaminophen hepatotoxicity. *Clin Liver Dis*. 2007;11(3):525–548. doi:10.1016/j.cld.2007.06.006.
31. Prescott LF. Paracetamol: past, present, and future. *Am J Ther*. 2000;7(2):143–147. doi:10.1097/00045391-200007020-00009.
32. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. *Nat Rev Dis Primers*. 2019;5(1):58. doi:10.1038/s41572-019-0105-0.
33. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. *Gastroenterology*. 2014;146(4):914–928. doi:10.1053/j.gastro.2013.12.032.
34. Navarro VJ, Senior JR. Drug-related hepatotoxicity. *N Engl J Med*. 2006;354(7):731–739. doi:10.1056/NEJMra052270.
35. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. *Clin Pharmacol Ther*. 2011;89(6):806–815. doi:10.1038/clpt.2011.58.
36. Zimmerman HJ. Drug-induced liver disease. In: Zimmerman HJ, editor. *Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 63–74.
37. Pessayre D, Fromenty B. NASH: a mitochondrial disease. *J Hepatol*. 2005;42(6):928–940. doi:10.1016/j.jhep.2005.03.004.
38. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. *Fundam Clin Pharmacol*. 2008;22(4):335–353. doi:10.1111/j.1472-8206.2008.00608.x.

39. Will Y, Dykens JA, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitor sunitinib on mitochondrial function, oxidative stress, and apoptosis in cardiomyocytes and hepatocytes. *Toxicol Sci.* 2008;106(1):153–165. doi:10.1093/toxsci/kfn153.
40. Dykens JA, Will Y. Drug-induced mitochondrial toxicity in the geriatric population: biomarkers and translational models. *Expert Opin Drug Metab Toxicol.* 2007;3(3):361–372. doi:10.1517/17425255.3.3.361.
41. Hoofnagle JH, Björnsson ES. Drug-induced liver injury types and phenotypes. *N Engl J Med.* 2019;381(3):264–273. doi:10.1056/NEJMra1816149.
42. European Medicines Agency. EudraVigilance Pharmacovigilance database. Available from: <https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>.
43. Larson AM. Acetaminophen hepatotoxicity. *Clin Liver Dis.* 2007;11(3):525–548. doi:10.1016/j.cld.2007.06.006.
44. Smith D, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. *Nat Rev Drug Discov.* 2010;9(12):929-939. doi:10.1038/nrd3287.
45. Di L. An update on the importance of plasma protein binding in drug discovery and development. *Expert Opin Drug Discov.* 2021;16(12):1453-1465. doi:10.1080/17460441.2021.1961741.
46. DeVane CL. Clinical significance of drug binding, protein binding, and binding displacement drug interactions. *Psychopharmacol Bull.* 2002;36(3):5-21.
47. Svennebring A. The impact of plasma protein binding on toxic plasma drug concentration. *Int J Comput Biol Drug Des.* 2016;9(4):345-368. doi:10.1504/IJCBDD.2016.080106.

48. Madak JT, Neamati N. Membrane permeable lipophilic cations as mitochondrial directing groups. *Curr Top Med Chem.* 2015;15(8):745-766. doi:10.2174/1568026615666150302105622.
49. McStay GP. Contributions of plasma protein binding and membrane transporters to drug-induced mitochondrial toxicity. In: Will Y, Dykens JA, editors. Mitochondrial dysfunction caused by drugs and environmental toxicants, Volume I. Hoboken (NJ): John Wiley & Sons; 2018. p. 3–14.
50. Koehn, L.M. (2022). ABC Transporters: An Overview. In: Talevi, A. (eds) The ADME Encyclopedia. Springer, Cham. https://doi.org/10.1007/978-3-030-84860-6_76.
51. Shi S, Wang L, van der Laan LJW, Pan Q, Verstegen MMA. Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. *Transplantation.* 2021 Nov 1;105(11):2362-2373. doi: 10.1097/TP.0000000000003691. PMID: 33577251; PMCID: PMC9005104.
52. Mooli RGR, Mukhi D, Ramakrishnan SK. Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases. *Compr Physiol.* 2022 Mar 29;12(2):3167-3192. doi: 10.1002/cphy.c200021. PMID: 35578969; PMCID: PMC10074426.
53. Li S, Tan HY, Wang N, et al. The Role of Oxidative Stress and Antioxidants in Liver Diseases. *Int J Mol Sci.* 2015;16(11):26087-26124. Published 2015 Nov 2. doi:10.3390/ijms161125942.
54. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. *Drug Metab Dispos.* 2003;31(12):1499–1506. doi:10.1124/dmd.31.12.1499.
55. Tujios SR, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. *Nat Rev Gastroenterol Hepatol.* 2011;8(4):202–211. doi:10.1038/nrgastro.2011.23.
56. McKee EE, Ferguson M, Bentley AT, Marks TA. Inhibition of mammalian mitochondrial protein synthesis by chloramphenicol. *Biochem Pharmacol.* 2006;71(9):1248–1257. doi: 10.1016/j.bcp.2006.01.012.

57. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, et al. Clinical and histopathologic features of tetracycline-induced liver injury. *Clin Gastroenterol Hepatol*. 2011;9(12):1036–1041.e1. doi: 10.1016/j.cgh.2011.08.027.
58. Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of oxidant-induced cell death. *J Biol Chem*. 2008;283(20):13561–13570. doi:10.1074/jbc.M800073200.
59. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. *Nat Rev Drug Discov*. 2003;2(10):812–822. doi:10.1038/nrd1201.
60. Galluzzi L, Kepp O, Kroemer G. Mitochondrial regulation of cell death: a brief overview. *Cold Spring Harb Perspect Biol*. 2012;4(9): a011104. doi:10.1101/cshperspect. a011104.
61. Guengerich FP. Cytochrome P450 and chemical toxicology. *Chem Res Toxicol*. 2008;21(1):70–83. doi:10.1021/tx700079z.
62. Pessayre D, Fromenty B. Mitochondrial injury in steatohepatitis. *Eur J Gastroenterol Hepatol*. 2005;17(10):1095–1101. doi:10.1097/00042737-200510000-00004.
63. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. *Drug Metab Rev*. 2012;44(1):88–106. doi:10.3109/03602532.2011.602688.
64. Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. *Semin Liver Dis*. 2009;29(2):141–154. doi:10.1055/s-0029-1214370.
65. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. *Semin Liver Dis*. 2009;29(4):400–411. doi:10.1055/s-0029-1240008.
66. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. *Curr Opin Allergy Clin Immunol*. 2014;14(4):286–292. doi:10.1097/ACI.0000000000000071

67. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. *Nat Genet.* 2009;41(7):816–819. doi:10.1038/ng.379.
68. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. *J Hepatol.* 2005;43(5):901–910. doi: 10.1016/j.jhep.2005.08.002.
69. Pessayre D, Fromenty B. Mitochondrial injury in drug-induced liver disease. *Drug Metab Rev.* 2005;37(2):311–342. doi:10.1081/DMR-200047936.
70. Robin ED, Wong R. Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. *J Cell Physiol.* 1988;136(3):507–513. doi:10.1002/jcp.1041360316.
71. Wallace DC. Mitochondria as metabolic and signaling organelles in health and disease. *J Clin Invest.* 2013;123(4):1405–1412. doi:10.1172/JCI61125.
72. Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, et al. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the International Transporter Consortium. *Clin Pharmacol Ther.* 2018;104(5):900–915. doi: 10.1002/cpt.1115.
73. Otsuka M, Matsumoto T, Morimoto R, et al. The role of ABCB1, ABCG2, and SLC transporters in drug absorption, distribution, and elimination. *Membranes (Basel).* 2024;14(11):223. doi: 10.3390/membranes14110223.
74. Cederbaum AI. Role of mitochondrial cytochrome P450 2E1 in healthy and diseased liver. *Cells.* 2022;11(2):288. doi: 10.3390/cells11020288.
75. Ramachandran A, Visschers RGJ, Duan L, Akakpo JY, Jaeschke H. Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives. *J Clin Transl Res.* 2018;4(1):75-100. doi:10.18053/jctres.04.201801.005.
76. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. *Cell.* 2012;148(6):1145–1159. doi: 10.1016/j.cell.2012.02.035

77. Shokolenko IN, Wilson GL, Alexeyev MF. Aging: a mitochondrial DNA perspective, critical analysis and an update. *World J Exp Med*. 2014;4(4):46–57. doi:10.5493/wjem.v4.i4.46.
78. Bernardi P, Rasola A, Forte M, Lippe G. The mitochondrial permeability transition pore: channel formation by F-ATP synthase, integration in signal transduction, and role in pathophysiology. *Physiol Rev*. 2015;95(4):1111–1155. doi:10.1152/physrev.00001.2015.
79. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science*. 2004;305(5684):626–629. doi:10.1126/science.1099320.
80. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, et al. Clinical and histopathologic features of tetracycline-induced liver injury. *Clin Gastroenterol Hepatol*. 2011;9(12):1036–1041.e1. doi: 10.1016/j.cgh.2011.08.027.
81. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. *J Hepatol*. 2011;54(4):773–794. doi: 10.1016/j.jhep.2010.11.006.
82. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats: possible role of oxidative stress. *J Pharmacol Exp Ther*. 2002;303(2):555–562. doi:10.1124/jpet.102.038307.
83. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J*. 2009;417(1):1–13. doi:10.1042/BJ20081386.
84. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med*. 1991;11(1):81–128. doi:10.1016/0891-5849(91)90192-6.
85. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. *Science*. 2012;337(6098):1062–1065. doi:10.1126/science.1219855.

86. Wu H, Wang MC, Bohmann D. JNK protects *Drosophila* from oxidative stress by controlling the mitochondrial permeability transition pore. *Nature*. 2009;457(7222):476–480. doi:10.1038/nature07568.
87. Chen H, Chan DC. Mitochondrial dynamics in mammals. *Curr Top Dev Biol*. 2004; 59:119–144. doi:10.1016/S0070-2153(04)59005-4.
88. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. *Cell Death Differ*. 2013;20(1):31–42. doi:10.1038/cdd.2012.81.
89. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. *Pharmacol Ther*. 1995;67(1):101–154. doi:10.1016/0163-7258(95)00012-6.
90. Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. *Liver Int*. 2017;37(11):1582–1590. doi:10.1111/liv.13426.
91. U.S. Food and Drug Administration. Guidance for industry: Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products content and format. 2011.
92. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. *N Engl J Med*. 1998;338(13):916–917. doi:10.1056/NEJM199803263381314.
93. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. *Drug Saf*. 1999;21(5):407–421. doi:10.2165/00002018-199921050-00005.
94. O'Mara E, Weitz J, Hudgens S, Knabb RM, Atkinson J, Choi Y, et al. Hepatic effects of ximelagatran: observations from clinical trials. *J Clin Pharmacol*. 2005;45(4):399–408. doi:10.1177/0091270004273820.
95. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. *Neurology*. 1987;37(3):379–385. doi:10.1212/WNL.37.3.379.

96. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. *N Engl J Med*. 1995;333(17):1099–1105. doi:10.1056/NEJM199510263331702.
97. ICH Harmonised Tripartite Guideline S7A. Safety pharmacology studies for human pharmaceuticals. International Conference on Harmonisation. 2000.
98. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems>.
99. European Medicines Agency. EudraVigilance Pharmacovigilance database. Available from: <https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance>.
100. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: The largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. *Drug Discov Today*. 2016;21(4):648–653. doi: 10.1016/j.drudis.2016.02.015.
101. Shinozawa T, Kimura M, Cai Y, Saiki N, Yoneyama Y, Ishida S, et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell-derived hepatocytes. *Gastroenterology*. 2021;160(3):831–846.e10. doi: 10.1053/j.gastro.2020.10.034.
102. Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, et al. Clinical and histopathologic features of tetracycline-induced liver injury. *Clin Gastroenterol Hepatol*. 2011;9(12):1036–1041.e1. doi: 10.1016/j.cgh.2011.08.027.
103. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. *N Engl J Med*. 2005;353(21):2305–2306. doi:10.1056/NEJMc051789.
104. Holla V, Soong R, Wu J, Zhang Q, Ruan X, Du W, et al. Trovafloxacin-induced mitochondrial toxicity in primary human hepatocytes. *Toxicol Sci*. 2015;143(1):81–91. doi:10.1093/toxsci/kfu203.

105. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU). *N Engl J Med*. 1995;333(17):1099–1105. doi:10.1056/NEJM199510263331702.
106. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? *World J Gastroenterol*. 2010;16(45):5651–5661. doi:10.3748/wjg.v16.i45.5651.
107. Will Y, Shields JE, Wallace KB. Drug-induced mitochondrial toxicity in the cardiac context: a review of evidence and screening strategies. *Toxicol Appl Pharmacol*. 2022; 454:116274. doi: 10.1016/j.taap.2022.116274.
108. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. *Expert Rev Mol Diagn*. 2007;7(2):161–175. doi:10.1586/14737159.7.2.161.
109. U.S. Food and Drug Administration. NDA 21-39 Acetadote. FDA.gov [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-39_Acetadote.cfm. Accessed 2017 Jun 26.
110. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. *Clin Pharmacol Ther*. 1974;16(4):676–684. doi: 10.1002/cpt1974164676.
111. Remien CH, Adler FR, Waddoups L, Box TD, Sussman NL. Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death. *Hepatology*. 2012;56(3):727–734. doi: 10.1002/hep.25656.
112. Lee WM. Acetaminophen (APAP) hepatotoxicity—Isn't it time for APAP to go away? *J Hepatol*. 2017;67(6):1324–1331. doi: 10.1016/j.jhep.2017.07.005.
113. Visser K, van der Heijde D. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. *Clin Exp Rheumatol*. 2009;27(6):1017–1025.

114. Masubuchi Y, Suda C, Horie T. Involvement of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. *J Pharmacol Exp Ther.* 2002;303(2):555–562. doi:10.1124/jpet.102.038307.
115. Nadanaciva S, Will Y. Investigating mitochondrial dysfunction for screening and safety assessment of drugs. *Cell Health Cytoskelet.* 2010; 2:109–122. doi:10.2147/CHC.S9637.
116. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. *Nat Med.* 1995;1(5):417–422. doi: 10.1038/nm0595-417.
117. Svennebring A. The impact of plasma protein binding on toxic plasma drug concentration. *Int J Comput Biol Drug Des.* 2016;9(4):345-368. doi:10.1504/IJCBDD.2016.080106.
118. Madak JT, Neamati N. Membrane permeable lipophilic cations as mitochondrial directing groups. *Curr Top Med Chem.* 2015;15(8):745-766. doi:10.2174/1568026615666150302105622.
119. Carbonera D, Angrilli A, Azzone GF. Mechanism of nitrofurantoin toxicity and oxidative stress in mitochondria. *Biochim Biophys Acta.* 1988;936(1):139–147. doi: 10.1016/0005-2728(88)90261-7.
116. Machado AC, Caseli L. Interaction of nitrofurantoin with lipid Langmuir monolayers as cellular membrane models distinguished with tensiometry and infrared spectroscopy. *Colloids Surf B Biointerfaces.* 2020; 188:110794. doi: 10.1016/j.colsurfb.2020.110794.
120. Sztajnkrzycki MD. Valproic acid toxicity: overview and management. *J Toxicol Clin Toxicol.* 2002;40(6):789–801.
121. Silva MFB, Aires CCP, Luis PBM, Ruiter JPN, IJlst L, Duran M, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. *J Inher Metab Dis.* 2008;31(2):205–216. doi: 10.1007/s10545-008-0841-x.

122. Caiment F, Wolters J, Smit E, Schrooders Y, Kleinjans J, van den Beucken T. Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro: impact of C/EBP α -controlled gene expression. *Arch Toxicol.* 2020;94(10):3463–3473. doi: 10.1007/s00204-020-02835-x.
123. Ezhilarasan D, Mani U. Valproic acid-induced liver injury: an insight into molecular toxicological mechanism. *Environ Toxicol Pharmacol.* 2022; 95:103967. doi: 10.1016/j.etap.2022.103967.
124. Boelsterli UA. Mechanistic toxicology of nimesulide. *Toxicol Lett.* 2002;127(1–3):121–132. doi:10.1016/S0378-4274(01)00488-2.
125. Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. *Pharmacol Toxicol.* 2003;93(3):105–115. doi:10.1034/j.1600-0773.2003.930301. x.
126. Chopra I, Hodgson J, Metcalf B, Poste G. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. *Antimicrob Agents Chemother.* 1997;41(3):497–503. doi:10.1128/AAC.41.3.497.
127. Yunis AA. Chloramphenicol toxicity: 25 years of research. *Am J Med.* 1989;87(3N):44N–48N. doi:10.1016/S0002-9343(89)80694-0.
128. Murray PR, Rosenthal KS, Pfaller MA. *Medical Microbiology*. 9th ed. Elsevier; 2020. p. 133–135.
129. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. *Cell.* 2012;148(6):1145–1159. doi: 10.1016/j.cell.2012.02.035.
130. Will Y, Hynes J, Ogurtsov VI, Papkovsky DB. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. *Nat Protoc.* 2006;1(6):2563–2572. doi:10.1038/nprot.2006.307.
117. Robinson AJ, Kunji ER. Mitochondrial carriers in the cytoplasmic state have a common substrate binding site. *Proc Natl Acad Sci U S A.* 2006;103(8):2617–2622. doi:10.1073/pnas.0511014103.

118. Bansal AK, Bansal M, Soni G, Bhatnagar D. Protective role of Vitamin E pretreatment on N-nitrosodiethylamine induced oxidative stress in rat liver. *Chem Biol Interact.* 2005;156(2–3):101–111. doi: 10.1016/j.cbi.2005.07.001.
119. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. *Biochimie.* 2002;84(2–3):131–141. doi:10.1016/S0300-9084(02)01369-X.
120. Andersson J, Boman G, Juhlin L, Norrby SR. Adverse reactions to chloramphenicol in Sweden 1972–1982. *J Antimicrob Chemother.* 1984;13 Suppl A:115–122. doi: 10.1093/jac/13.suppl_A.115.
121. Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. *Drug Metab Dispos.* 2003;31(8):1035–1042. doi:10.1124/dmd.31.8.1035.
122. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. *Cell Biol Toxicol.* 2012;28(2):69–87. doi:10.1007/s10565-011-9208-4.
123. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. *Curr Drug Metab.* 2003;4(4):292–312. doi:10.2174/1389200033489436.
124. Anthérieu S, Chesné C, Li R, Guguen-Guillouzo C, Guillouzo A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. *Toxicol In Vitro.* 2012;26(8):1278–1285. doi: 10.1016/j.tiv.2012.07.001.
125. Shinozawa T, Kimura M, Cai Y, Saiki N, Yoneyama Y, Ishida S, et al. High-fidelity drug-induced liver injury screen using human pluripotent stem cell–derived hepatocytes. *Gastroenterology.* 2021;160(3):831–846.e10. doi: 10.1053/j.gastro.2020.10.034.

126. Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. *Sci Rep.* 2016; 6:25187. doi:10.1038/srep25187.
127. Plaa GL, Hewitt WR. Detection and evaluation of chemically induced liver injury. In: Hayes AW, editor. *Principles and Methods of Toxicology*. 3rd ed. New York: Raven Press; 1994. p. 843–887.
128. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J.* 2009;417(1):1–13. doi:10.1042/BJ20081386.
129. Halliwell B, Gutteridge JMC. *Free Radicals in Biology and Medicine*. 5th ed. Oxford University Press; 2015.
130. Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications—a review. *Mar Drugs.* 2014;12(1):128–152. doi:10.3390/md12010128.
131. Kidd P. Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. *Altern Med Rev.* 2011;16(4):355–364.
132. Wolf AM, Asoh S, Hiranuma H, Ohsawa I, Iio K, Satou A, et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. *J Nutr Biochem.* 2010;21(5):381–389. doi: 10.1016/j.jnutbio.2009.01.011.
133. Hussein G, Nakamura M, Zhao Q, Iguchi T, Goto H, Sankawa U, et al. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. *Biol Pharm Bull.* 2005;28(1):47–52. doi:10.1248/bpb.28.47.
134. Zhang L, Wang H, Fan Y, Gao Y, Li X, Hu Z, et al. Astaxanthin protects against MPP⁺-induced oxidative stress in PC12 cells via the Nrf2/HO-1 pathway. *J Neurochem.* 2015;133(5):848–855. doi:10.1111/jnc.13098.
135. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol.* 2008;585(2–3):325–337. doi: 10.1016/j.ejphar.2008.03.008.

136. Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. *Obesity (Silver Spring)*. 2008;16(9):2081–2087. doi:10.1038/oby.2008.315.
137. Domitrović R, Jakovac H, Tomac J, Šain I. Liver fibrosis in mice induced by carbon tetrachloride: protective role of quercetin. *J Nutr Biochem*. 2012;23(8):1048–1056. doi: 10.1016/j.jnutbio.2011.05.008.
138. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. *Biochem Pharmacol*. 2012;83(1):6–15. doi: 10.1016/j.bcp.2011.08.010.
139. Lee DH, Kim JH, Park JS, Choi JY, Kang KS, Lee YS. Synergistic hepatoprotective effects of combined astaxanthin and quercetin against oxidative liver injury. *Food Chem Toxicol*. 2020; 146:111803. doi: 10.1016/j.fct.2020.111803.
140. Schomaker SJ, Warner RL, Bock J, Johnson K, Potter DM, Van Winkle J, et al. Assessment of emerging biomarkers of liver injury in human subjects. *Toxicol Sci*. 2013;132(2):276–283. doi:10.1093/toxsci/kft003.
141. U.S. Food and Drug Administration. Biomarker Qualification: Evidentiary Framework. 2018. Available at: <https://www.fda.gov/>.
142. Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. *Annu Rev Physiol*. 2016; 78:223–241. doi:10.1146/annurev-physiol-021115-105339.
143. West AP, Shadel GS. and inflammatory pathology. *Nat Rev Immunol*. 2017;17(6):363–375. doi:10.1038/nri.2017.21.
144. Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. *Ann N Y Acad Sci*. 2008; 1147:321–334. doi:10.1196/annals.1427.006.
145. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid Med Cell Longev*. 2014; 2014:360438. doi:10.1155/2014/360438.

146. Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2'-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoicol Rev.* 2009;27(2):120–139. doi:10.1080/10590500902885684.
147. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. *Biochem J.* 2011;435(2):297–312. doi:10.1042/BJ20110162.
148. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. *Biochem J.* 1995;312(1):163–167. doi:10.1042/bj3120163.
149. Iotti S, Frassinetti C, Sabatini A, Vacca A, Barbiroli B. Quantitative mathematical expressions for accurate in vivo assessment of cytosolic [ADP] and ΔG of ATP hydrolysis in the human brain and skeletal muscle. *Biochim Biophys Acta.* 2005;1708(2):164–177. doi: 10.1016/j.bbabbio.2005.02.004.
150. U.S. Food and Drug Administration. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. Available at: <https://www.fda.gov/>.
151. Lee DH, Kim JH, Park JS, Choi JY, Kang KS, Lee YS. Synergistic hepatoprotective effects of combined astaxanthin and quercetin against oxidative liver injury. *Food Chem Toxicol.* 2020; 146:111803. doi: 10.1016/j.fct.2020.111803.
152. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. *Hepatology.* 2016;63(2):590–6.
153. Donato MT, Gómez-Lechón MJ. Drug-induced liver injury by inhibition of mitochondrial function: mechanisms, biomarkers, and safety testing in liver cells. *Pharmaceutics.* 2022;14(2):396. <https://doi.org/10.3390/pharmaceutics14020396>.
154. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. *Gastroenterology.* 2013;144(7):1419–25. <https://doi.org/10.1053/j.gastro.2013.02.006>.

155. Wu L, et al. Astaxanthin attenuates hepatic damage in NAFLD via FGF21/PGC-1 α pathway. *Br J Pharmacol*. 2020;177(16):3760–77. <https://doi.org/10.1111/bph.15099>.
156. Zhao X, et al. Quercetin as a protective agent for liver diseases. *Phytother Res*. 2021;35(9):4727–47. <https://doi.org/10.1002/ptr.7104>.
157. Huang YS. Recent progress in genetic and non-genetic predictors of drug-induced liver injury. *Clin Liver Dis (Hoboken)*. 2020;15(4):174–80. <https://doi.org/10.1002/cld.914>.
158. Rana SV, Singh R, Verma S. Mitochondrial toxicity of antibiotics: Mechanisms and implications. *Biochem Pharmacol*. 2022; 195:114850. <https://doi.org/10.1016/j.bcp.2021.114850>.
159. FDA Drug Safety Communication: Valproate products boxed warning. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018081s068lbl.pdf.
160. Wu L, et al. Astaxanthin attenuates hepatic damage in NAFLD via FGF21/PGC-1 α pathway. *Br J Pharmacol*. 2020;177(16):3760–77. <https://doi.org/10.1111/bph.15099>.
161. Zhao X, et al. Quercetin as a protective agent for liver diseases. *Phytother Res*. 2021;35(9):4727–47. <https://doi.org/10.1002/ptr.7104>.

4.